Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-011 + ABBV-181 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-011 | SC-011|ABBV011|ABBV 011 | ABBV-011 (SC-011) is an antibody-drug conjugate of an undisclosed tumor-associated antigen and a cytotoxic agent (NCI Drug Dictionary). | ||
ABBV-181 | ABBV181|ABBV 181|Budigalimab | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 87 | ABBV-181 (budigalimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03639194 | Phase I | ABBV-011 + ABBV-181 ABBV-011 | A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | 3 |